Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Altamira Therapeutics Ltd. (CYTOF) had Stock-Based Compensation of $0.26M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$0.25M |
|
$0.10M |
|
$6.88M |
|
$7.13M |
|
$2.31M |
|
-- |
|
$0.75M |
|
$3.06M |
|
$4.07M |
|
$-0.55M |
|
$4.07M |
|
5.71M |
|
| Cash Flow Statement Financials | |
$-1.38M |
|
$-0.00M |
|
$0.37M |
|
$1.00M |
|
$0.00M |
|
$-0.99M |
|
|
Stock-Based Compensation |
$0.26M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|